View More Recent Stories

Apr 24, 2019 04:10PM TherapeuticsMD Closes $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
Apr 17, 2019 07:07AM TherapeuticsMD (TXMD) Announces $300M Commitment Letter for Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
Apr 17, 2019 07:05AM TherapeuticsMD Signs Binding Commitment Letter for $300 Million Non-Dilutive Term Loan Financing Facility with TPG Sixth Street Partners
Apr 17, 2019 07:04AM TherapeuticsMD (TXMD) Confirms Commercial Availability of BIJUVA in the U.S.
Apr 17, 2019 07:00AM TherapeuticsMD Announces Commercial Availability of BIJUVA™ in the U.S.
Mar 25, 2019 07:00AM TherapeuticsMD Announces Oral and Poster Presentations on BIJUVA™ and ANNOVERA™ at the Endocrine Society 2019 Annual Meeting
Mar 8, 2019 07:00AM TherapeuticsMD Announces Oral Presentations on BIJUVA and ANNOVERA, and Poster Presentations Related to Menopause Symptoms and Treatments at 2019 ISSWSH/ISSM Joint Meeting
Feb 28, 2019 07:00AM TherapeuticsMD Announces Participation in Two Upcoming Investor Conferences
Feb 21, 2019 04:05PM TherapeuticsMD Announces Fourth Quarter and Full-Year 2018 Financial Results
Feb 8, 2019 07:00AM TherapeuticsMD to Report Fourth Quarter and Full Year 2018 Results on February 21, 2019
Jan 3, 2019 07:00AM TherapeuticsMD Announces Participation at 37th Annual J.P. Morgan Healthcare Conference
Nov 12, 2018 04:30PM TherapeuticsMD Announces Participation in Three Upcoming Investor Conferences
Nov 7, 2018 04:05PM TherapeuticsMD Announces Third Quarter 2018 Financial Results
Oct 30, 2018 07:00AM TherapeuticsMD to Report Third Quarter 2018 Financial Results on November 7, 2018
Oct 29, 2018 06:06AM TherapeuticsMD (TXMD) Reports FDA Approval of TX-001HR: BIJUVA (Estradiol & Progesterone) Capsules for Treatment of Moderate to Severe Vasomotor Symptoms
Oct 29, 2018 06:00AM TherapeuticsMD Announces FDA Approval of TX-001HR: BIJUVA™ (Estradiol and Progesterone) Capsules for the Treatment of Moderate to Severe Vasomotor Symptoms Due to Menopause
Sep 28, 2018 07:00AM TherapeuticsMD Announces Multiple Presentations Related to Imvexxy™ and TX-001HR at the 2018 Annual Meeting of the North American Menopause Society
Sep 27, 2018 04:10PM TherapeuticsMD (TXMD) Announces Preliminary Discussions with FDA for Proposed Label for TX-001HR
Sep 27, 2018 04:05PM TherapeuticsMD Enters Into Label Discussions for TX-001HR
Sep 25, 2018 07:00AM TherapeuticsMD to Present at 2018 Cantor Global Healthcare Conference
Sep 20, 2018 07:05AM TherapeuticsMD (TXMD) Announces FDA has Granted Annovera Marketing Exclusivity as New Chemical Entity
Sep 20, 2018 07:00AM TherapeuticsMD Announces the FDA has Granted AnnoveraTM Marketing Exclusivity as a New Chemical Entity
Sep 13, 2018 07:00AM TherapeuticsMD Announces Commercial Availability of Imvexxy™ 4 mcg
Aug 22, 2018 07:00AM TherapeuticsMD to Present at 13th Annual Wells Fargo Securities Healthcare Conference
Aug 10, 2018 03:06PM TherapeuticsMD (TXMD) Confirms FDA Approval of ANNOVERA for Birth Control
Aug 10, 2018 03:05PM TherapeuticsMD Announces FDA Approval of ANNOVERA™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System) for Birth Control
Jul 31, 2018 04:55PM TherapeuticsMD (TXMD) Licenses Population Council’s Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System
Jul 31, 2018 04:15PM TherapeuticsMD Licenses Population Council’s Novel Segesterone Acetate/ Ethinyl Estradiol One-Year Vaginal Contraceptive System
Oct 6, 2017 10:00AM TherapeuticsMD, Inc. (Nasdaq: TXMD) to Ring The Nasdaq Stock Market Opening Bell in Celebration of Its Listing On Nasdaq
View More Recent Stories